Hot products 
-
Mouse Anti-ARID3A Antibody (A4) (CBMAB-0128-YC)
-
Mouse Anti-AGO2 Recombinant Antibody (V2-634169) (CBMAB-AP203LY)
-
Mouse Anti-ATP1B3 Recombinant Antibody (1E9) (CBMAB-A4021-YC)
-
Rabbit Anti-DLK1 Recombinant Antibody (9D8) (CBMAB-D1061-YC)
-
Rabbit Anti-ENO2 Recombinant Antibody (BA0013) (CBMAB-0272CQ)
-
Mouse Anti-DMD Recombinant Antibody (D1190) (CBMAB-D1190-YC)
-
Mouse Anti-Acetyl SMC3 (K105/K106) Recombinant Antibody (V2-634053) (CBMAB-AP052LY)
-
Rabbit Anti-ALK (Phosphorylated Y1278) Recombinant Antibody (D59G10) (PTM-CBMAB-0035YC)
-
Mouse Anti-ABCA3 Recombinant Antibody (V2-178911) (CBMAB-A0145-YC)
-
Mouse Anti-ALX1 Recombinant Antibody (96k) (CBMAB-C0616-FY)
-
Mouse Anti-ATM Recombinant Antibody (2C1) (CBMAB-A3970-YC)
-
Mouse Anti-ALDOA Recombinant Antibody (A2) (CBMAB-A2316-YC)
-
Mouse Anti-CD33 Recombinant Antibody (6C5/2) (CBMAB-C8126-LY)
-
Mouse Anti-CD1C Recombinant Antibody (L161) (CBMAB-C2173-CQ)
-
Mouse Anti-CCS Recombinant Antibody (CBFYC-1093) (CBMAB-C1150-FY)
-
Mouse Anti-ALB Recombinant Antibody (V2-55272) (CBMAB-H0819-FY)
-
Mouse Anti-APCS Recombinant Antibody (CBYC-A663) (CBMAB-A3054-YC)
-
Mouse Anti-CD24 Recombinant Antibody (ALB9) (CBMAB-0176CQ)
-
Human Anti-SARS-CoV-2 S1 Monoclonal Antibody (CBFYR-0120) (CBMAB-R0120-FY)
-
Mouse Anti-APOE Recombinant Antibody (A1) (CBMAB-0078CQ)
Endometrial Cancer
Fig.1 Endometrial cancer
Endometrial cancer is a cancer originating from the endometrium, which is the lining of the womb and uterus. The first sign is most abnormal vaginal bleeding but not associated with menstrual periods. Other symptoms include pain with urination, pelvic pain or sexual intercourse. Endometrial cancer occurs overwhelmingly after menopause. About 40% of cases are related to obesity. Besides it is also associated with diabetes, excessive estrogen exposure and high blood pressure. Hereditary causes contribution to 2–10% of the endometrial cancer cases. The most common type of endometrial cancer is endometrioid carcinoma, which making up more than 80% of cases. The five-year survival rate for endometrial adenocarcinoma following appropriate treatment is around 80%. Prognostic markers, like Serum HE4 have been studied recently.
Loading...



